1. Home
  2. SDEV vs CRDF Comparison

SDEV vs CRDF Comparison

Compare SDEV & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stablecoin Development Corporation Common Stock

SDEV

Stablecoin Development Corporation Common Stock

N/A

Current Price

$0.76

Market Cap

65.3M

Sector

Health Care

ML Signal

N/A

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

N/A

Current Price

$0.72

Market Cap

67.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SDEV
CRDF
Founded
2000
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
65.3M
67.1M
IPO Year
2007
2012

Fundamental Metrics

Financial Performance
Metric
SDEV
CRDF
Price
$0.76
$0.72
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
★ $6.28
AVG Volume (30 Days)
★ 11.4M
364.0K
Earning Date
10-29-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 27.37
EPS
★ 2.65
N/A
Revenue
★ $370,000.00
$365,993.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$11.81
P/E Ratio
$0.29
★ N/A
Revenue Growth
N/A
★ 49.61
52 Week Low
$0.76
$0.72
52 Week High
$9.82
$3.31

Technical Indicators

Market Signals
Indicator
SDEV
CRDF
Relative Strength Index (RSI) 38.44 30.76
Support Level N/A N/A
Resistance Level $1.28 $1.13
Average True Range (ATR) 0.10 0.06
MACD -0.01 -0.00
Stochastic Oscillator 6.01 5.60

Price Performance

Historical Comparison
SDEV
CRDF

About SDEV Stablecoin Development Corporation Common Stock

Stablecoin Development Corp is an on-chain holding company focused on long-duration participation in protocol-aligned digital asset ecosystems. The Company's initial digital asset focus is the Sky protocol ecosystem, with SKY as its core holding. Through staking and other on-chain activities, the Company seeks to generate protocol-level economic returns while maintaining rigorous governance and risk management oversight.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.

Share on Social Networks: